Greg Kearns

479 total citations
6 papers, 389 citations indexed

About

Greg Kearns is a scholar working on Neurology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Greg Kearns has authored 6 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Neurology, 2 papers in Pharmacology and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Greg Kearns's work include Antibiotics Pharmacokinetics and Efficacy (2 papers), Neurological disorders and treatments (2 papers) and Parkinson's Disease Mechanisms and Treatments (2 papers). Greg Kearns is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (2 papers), Neurological disorders and treatments (2 papers) and Parkinson's Disease Mechanisms and Treatments (2 papers). Greg Kearns collaborates with scholars based in United States, Netherlands and Switzerland. Greg Kearns's co-authors include Gerard P. Sexton, John G. Nutt, Jau‐Shin Lou, Barry Oken, Jau-Shin Lou, John N. van den Anker, Saskia N. de Wildt, Gideon Koren, Sandeep Dutta and Robin E. Pearce and has published in prestigious journals such as Movement Disorders, Clinical Neurophysiology and Archives of Disease in Childhood.

In The Last Decade

Greg Kearns

6 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Greg Kearns United States	6	257	125	100	48	40	6	389
Riccardo Cremascoli Italy	14	115 0.4×	123 1.0×	87 0.9×	167 3.5×	31 0.8×	30	411
M. Eckhardt Netherlands	6	147 0.6×	79 0.6×	48 0.5×	74 1.5×	105 2.6×	6	415
Margaret C. Lannon United States	11	325 1.3×	192 1.5×	36 0.4×	72 1.5×	21 0.5×	15	570
Jacob Shofany Italy	8	88 0.3×	119 1.0×	29 0.3×	96 2.0×	74 1.9×	9	403
Carl Nikolaus Homann Austria	8	190 0.7×	54 0.4×	62 0.6×	67 1.4×	13 0.3×	18	295
Satoshi MIYANO Japan	9	70 0.3×	106 0.8×	62 0.6×	89 1.9×	75 1.9×	50	478
Carlo Dallocchio Italy	11	257 1.0×	115 0.9×	23 0.2×	37 0.8×	40 1.0×	22	426
Rosa Cabanas‐Valdés Spain	14	146 0.6×	226 1.8×	87 0.9×	25 0.5×	39 1.0×	28	593
A. Petrelli Germany	6	187 0.7×	204 1.6×	18 0.2×	112 2.3×	34 0.8×	8	383
Sudhir Karthikeyan Canada	7	42 0.2×	68 0.5×	86 0.9×	45 0.9×	76 1.9×	15	344

Countries citing papers authored by Greg Kearns

Since Specialization

Citations

This map shows the geographic impact of Greg Kearns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Kearns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Kearns more than expected).

Fields of papers citing papers by Greg Kearns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Kearns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Kearns. The network helps show where Greg Kearns may publish in the future.

Co-authorship network of co-authors of Greg Kearns

This figure shows the co-authorship network connecting the top 25 collaborators of Greg Kearns. A scholar is included among the top collaborators of Greg Kearns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg Kearns. Greg Kearns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Mir, Fatima, Robin E. Pearce, Naila Baig‐Ansari, et al.. (2020). Serum amoxicillin levels in young infants (0–59 days) with sepsis treated with oral amoxicillin. Archives of Disease in Childhood. 105(12). 1208–1214. 6 indexed citations

2.

Liu, Wei, Sandeep Dutta, Greg Kearns, Walid M. Awni, & Kathleen Neville. (2014). Pharmacokinetics of hydrocodone/acetaminophen combination product in children ages 6-17 with moderate to moderately severe postoperative pain. The Journal of Clinical Pharmacology. 55(2). 204–211. 5 indexed citations

3.

Wildt, Saskia N. de, et al.. (2009). Ontogeny of midazolam glucuronidation in preterm infants. European Journal of Clinical Pharmacology. 66(2). 165–170. 22 indexed citations

4.

Lou, Jau‐Shin, et al.. (2003). Levodopa improves physical fatigue in Parkinson's disease: A double‐blind, placebo‐controlled, crossover study. Movement Disorders. 18(10). 1108–1114. 105 indexed citations

5.

Lou, Jau-Shin, et al.. (2003). Levodopa normalizes exercise related cortico-motoneuron excitability abnormalities in Parkinson's disease. Clinical Neurophysiology. 114(5). 930–937. 49 indexed citations

6.

Lou, Jau‐Shin, Greg Kearns, Barry Oken, Gerard P. Sexton, & John G. Nutt. (2001). Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Movement Disorders. 16(2). 190–196. 202 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact